Key result
The genotype 34LeuLeu of FXIII was associated with a significantly reduced risk of venous thrombosis (OR 0.42; 95% CI 0.20-0.89) in early middle-age Costa Rican patients.
Why the study?
Does the FXIII Val34Leu polymorphism reduce the risk of venous thrombosis in early middle-age Costa Rican patients?
Case-Control (n=253)
Does the FXIII Val34Leu polymorphism reduce the risk of venous thrombosis in early middle-age Costa Rican patients?
The FXIII Val34Leu polymorphism is associated with a protective effect against venous thrombosis in early middle-age Costa Rican patients, consistent with findings in other populations.
In this study, eight common polymorphisms associated with venous thrombosis (VT) and thrombophilia factors were analyzed in a Costa Rican case-control study. With the use of polymerase chain reaction (PCR) methods the polymorphisms were detected in 120 patients and 133 controls (mean age <40 years old). It was concluded that a high level of fibrinogen, antiphospholipid antibodies, family history, and the genotype 34LeuLeu of FXIII OR 0.42 (0.20-0.89) showed a significant effect on the risk of VT. Associations between the risk of VT and genetic polymorphisms have been established. Some of these polymorphisms are highly prevalent in Caucasians, but there is a significant geographic variation in their prevalence among different populations. The results of this study support the protective effect of FXIII Val34Leu polymorphism in VT. These findings are consistent with previous reports that included other populations.
No takes yet. Share an insight, caveat, or question.
Salazar‐Sánchez et al. (2006) conducted a case-control in Venous thrombosis (n=253). Genotype 34LeuLeu of FXIII vs. Controls without venous thrombosis was evaluated on Venous thrombosis (OR 0.42, 95% CI 0.20-0.89). The genotype 34LeuLeu of FXIII was associated with a significantly reduced risk of venous thrombosis (OR 0.42; 95% CI 0.20-0.89) in early middle-age Costa Rican patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: